Eli Lilly and Company (NYSE:LLY) Shares Sold by Moseley Investment Management Inc.

Moseley Investment Management Inc. reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 0.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,635 shares of the company’s stock after selling 28 shares during the quarter. Eli Lilly and Company comprises 1.1% of Moseley Investment Management Inc.’s investment portfolio, making the stock its 18th biggest holding. Moseley Investment Management Inc.’s holdings in Eli Lilly and Company were worth $2,806,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the business. Clarus Wealth Advisors lifted its holdings in shares of Eli Lilly and Company by 61.5% in the 4th quarter. Clarus Wealth Advisors now owns 1,184 shares of the company’s stock valued at $944,000 after buying an additional 451 shares during the period. Acropolis Investment Management LLC increased its stake in Eli Lilly and Company by 5.9% in the 4th quarter. Acropolis Investment Management LLC now owns 1,765 shares of the company’s stock valued at $1,363,000 after purchasing an additional 99 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its stake in Eli Lilly and Company by 25.3% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 13,085 shares of the company’s stock valued at $10,104,000 after purchasing an additional 2,642 shares in the last quarter. Park Avenue Securities LLC increased its stake in Eli Lilly and Company by 14.1% in the 4th quarter. Park Avenue Securities LLC now owns 19,274 shares of the company’s stock valued at $14,880,000 after purchasing an additional 2,381 shares in the last quarter. Finally, Kathmere Capital Management LLC increased its stake in Eli Lilly and Company by 5.8% in the 4th quarter. Kathmere Capital Management LLC now owns 4,148 shares of the company’s stock valued at $3,202,000 after purchasing an additional 229 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, January 1st. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Wolfe Research initiated coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $746.42 on Thursday. Eli Lilly and Company has a twelve month low of $612.70 and a twelve month high of $972.53. The stock has a market capitalization of $708.59 billion, a P/E ratio of 80.69, a PEG ratio of 2.99 and a beta of 0.41. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The business’s fifty day moving average price is $784.63 and its 200 day moving average price is $857.48.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 EPS. Eli Lilly and Company’s revenue was up 20.4% compared to the same quarter last year. As a group, research analysts anticipate that Eli Lilly and Company will post 13.18 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is currently 64.86%.

Eli Lilly and Company declared that its Board of Directors has approved a share buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.